Compare Stocks: NAMS, IBRX, PCVX, and KRYS

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
IBRX ImmunityBio	$10.51 +6.1%	$8.31	$1.95 ▼ $12.43	$11.14B	0.02	14.26 million shs	18.60 million shs
KRYS Krystal Biotech	$331.61 +1.3%	$340.04	$179.19 ▼ $382.54	$9.82B	0.5	306,995 shs	196,948 shs
NAMS NewAmsterdam Pharma	$21.58 +1.5%	$24.91	$20.91 ▼ $42.21	$2.58B	0.1	1.79 million shs	1.27 million shs
PCVX Vaxcyte	$71.38 +9.8%	$60.09	$39.87 ▼ $90.75	$10.62B	1.23	3.30 million shs	4.38 million shs

10 Stocks Powering The Next AI Boom

The AI boom is creating opportunities across semiconductors, cloud computing, enterprise software, infrastructure, cybersecurity, and automation.

Inside this report, you’ll find 10 companies positioned to benefit as artificial intelligence moves from hype to real-world deployment and becomes a core growth driver for corporate America.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
IBRX ImmunityBio	0.00%	+2.24%	+36.14%	+27.86%	+315.42%
KRYS Krystal Biotech	0.00%	+2.89%	-4.03%	-9.35%	+77.16%
NAMS NewAmsterdam Pharma	0.00%	-6.98%	-1.28%	-38.80%	-34.33%
PCVX Vaxcyte	0.00%	+26.38%	+21.19%	+22.62%	+75.21%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
IBRX ImmunityBio	$10.51 +6.1%	$8.31	$1.95 ▼ $12.43	$11.14B	0.02	14.26 million shs	18.60 million shs
KRYS Krystal Biotech	$331.61 +1.3%	$340.04	$179.19 ▼ $382.54	$9.82B	0.5	306,995 shs	196,948 shs
NAMS NewAmsterdam Pharma	$21.58 +1.5%	$24.91	$20.91 ▼ $42.21	$2.58B	0.1	1.79 million shs	1.27 million shs
PCVX Vaxcyte	$71.38 +9.8%	$60.09	$39.87 ▼ $90.75	$10.62B	1.23	3.30 million shs	4.38 million shs

10 Stocks Powering The Next AI Boom

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
IBRX ImmunityBio	0.00%	+2.24%	+36.14%	+27.86%	+315.42%
KRYS Krystal Biotech	0.00%	+2.89%	-4.03%	-9.35%	+77.16%
NAMS NewAmsterdam Pharma	0.00%	-6.98%	-1.28%	-38.80%	-34.33%
PCVX Vaxcyte	0.00%	+26.38%	+21.19%	+22.62%	+75.21%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
IBRX ImmunityBio	2.86	Moderate Buy	$14.20	35.11% Upside
KRYS Krystal Biotech	3.00	Buy	$377.20	13.75% Upside
NAMS NewAmsterdam Pharma	2.85	Moderate Buy	$49.00	127.06% Upside
PCVX Vaxcyte	2.63	Moderate Buy	$108.60	52.14% Upside

Current Analyst Ratings Breakdown

Latest NAMS, IBRX, PCVX, and KRYS Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
10/9/2026	KRYS Krystal Biotech	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Buy (B) ➝ Buy (B-)
10/6/2026	IBRX ImmunityBio	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (D-)
10/5/2026	PCVX Vaxcyte	Guggenheim Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Buy	$116.00 ➝ $125.00
10/5/2026	NAMS NewAmsterdam Pharma	Royal Bank Of Canada Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Outperform	$50.00 ➝ $42.00
10/5/2026	PCVX Vaxcyte	BTIG Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$89.00
10/5/2026	PCVX Vaxcyte	Needham & Company LLC Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Buy	$110.00 ➝ $122.00
10/2/2026	PCVX Vaxcyte	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (D-)
9/28/2026	PCVX Vaxcyte	Bank of America Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Buy	$133.00 ➝ $130.00
9/25/2026	IBRX ImmunityBio	Jefferies Financial Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Strong-Buy
9/25/2026	PCVX Vaxcyte	Needham & Company LLC Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$110.00
9/24/2026	KRYS Krystal Biotech	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Buy (B-) ➝ Buy (B)

(Data available from 10/11/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
IBRX ImmunityBio	$113.29M	98.32	N/A	N/A	($0.51) per share	-20.61
KRYS Krystal Biotech	$389.13M	25.22	$7.29 per share	45.49	$42.06 per share	7.88
NAMS NewAmsterdam Pharma	$22.50M	114.65	N/A	N/A	$5.97 per share	3.61
PCVX Vaxcyte	N/A	N/A	N/A	N/A	$20.51 per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
IBRX ImmunityBio	-$351.40M	-$0.97	N/A	N/A	N/A	-598.55%	N/A	-51.65%	11/3/2026 (Estimated)
KRYS Krystal Biotech	$204.83M	$7.98	41.56	36.20	N/A	54.82%	19.34%	17.65%	11/2/2026 (Estimated)
NAMS NewAmsterdam Pharma	-$203.82M	-$2.16	N/A	N/A	N/A	-3,644.21%	-34.81%	-31.50%	11/4/2026 (Estimated)
PCVX Vaxcyte	-$766.63M	-$7.63	N/A	N/A	N/A	N/A	-37.56%	-33.62%	11/3/2026 (Estimated)

Latest NAMS, IBRX, PCVX, and KRYS Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
11/4/2026	Q3 2026	NAMS NewAmsterdam Pharma	-$0.50	N/A	N/A	N/A	$7.54 million	N/A
11/3/2026	Q3 2026	IBRX ImmunityBio	-$0.07	N/A	N/A	N/A	$59.23 million	N/A
11/3/2026	Q3 2026	PCVX Vaxcyte	-$2.13	N/A	N/A	N/A	$12.50 million	N/A
11/2/2026	Q3 2026	KRYS Krystal Biotech	$1.86	N/A	N/A	N/A	$128.49 million	N/A
8/5/2026	Q2 2026	NAMS NewAmsterdam Pharma	-$0.4819	-$0.52	-$0.0381	-$0.52	$2.83 million	$3.70 million
8/5/2026	Q2 2026	PCVX Vaxcyte	-$2.06	-$1.97	+$0.09	-$1.97	$12.50 million	N/A
8/4/2026	Q2 2026	IBRX ImmunityBio	-$0.08	-$0.22	-$0.14	-$0.22	$49.70 million	$51.24 million
8/3/2026	Q2 2026	KRYS Krystal Biotech	$1.70	$1.79	+$0.09	$1.79	$120.93 million	$119.22 million

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
IBRX ImmunityBio	N/A	N/A	N/A	N/A	N/A
KRYS Krystal Biotech	N/A	N/A	N/A	N/A	N/A
NAMS NewAmsterdam Pharma	N/A	N/A	N/A	N/A	N/A
PCVX Vaxcyte	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
IBRX ImmunityBio	N/A	5.72	5.70
KRYS Krystal Biotech	N/A	8.32	7.96
NAMS NewAmsterdam Pharma	N/A	9.03	9.03
PCVX Vaxcyte	N/A	5.72	5.72

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
IBRX ImmunityBio	8.58%
KRYS Krystal Biotech	86.29%
NAMS NewAmsterdam Pharma	89.89%
PCVX Vaxcyte	96.78%

Insider Ownership

Company	Insider Ownership
IBRX ImmunityBio	66.10%
KRYS Krystal Biotech	13.10%
NAMS NewAmsterdam Pharma	12.74%
PCVX Vaxcyte	3.30%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
IBRX ImmunityBio	691	1.06 billion	359.28 million	Optionable
KRYS Krystal Biotech	295	29.60 million	25.72 million	Optionable
NAMS NewAmsterdam Pharma	100	119.54 million	104.31 million	Optionable
PCVX Vaxcyte	507	148.80 million	143.89 million	Optionable

NAMS, IBRX, PCVX, and KRYS Headlines

Recent News About These Companies

Vaxcyte Announces Closing of $1.15 Billion Public Offerings of Common Stock, Pre-Funded Warrants and Convertible Senior Notes, Including Full Exercise of Underwriters ...

October 9 at 12:39 AM | finance.yahoo.com

Weekly Buzz: RHHBY, NVS, PFE Win FDA Nod; CRBU Scales Back; PCVX, ABBV Report Positive Trial Data

October 9 at 2:31 PM | rttnews.com

Vaxcyte (NASDAQ:PCVX) Stock Jumps 8.7% - What's Next?

October 9 at 12:59 PM | marketbeat.com

Vaxcyte (NASDAQ:PCVX) Stock: Insider Jim Wassil Sells 18,000 Shares

October 9 at 4:11 AM | americanbankingnews.com

Vaxcyte (NASDAQ:PCVX) Stock: Insider Elvia Cowan Sells 19,000 Shares

October 9 at 4:11 AM | americanbankingnews.com

Guggenheim raised target for Vaxcyte stock from USD 116.00 to USD 125.00

October 8 at 7:29 PM | ad-hoc-news.deA

Why Vaxcyte (PCVX) Is Getting Attention Again

October 8 at 7:29 PM | finance.yahoo.com

Latham Advises on Vaxcyte’s Concurrent Public Offerings of Common Stock, Pre-Funded Warrants, and Convertible Senior Notes

October 8 at 9:27 AM | legaldesire.comL

Vaxcyte (NASDAQ:PCVX) EVP Sells $1,561,320.00 in Stock

October 8 at 6:07 AM | insidertrades.com

Vaxcyte (NASDAQ:PCVX) EVP Jim Wassil Sells 18,000 Shares of Stock

October 7, 2026 | marketbeat.com

Insider Selling: Vaxcyte (NASDAQ:PCVX) CAO Sells $1,648,060.00 in Stock

October 7, 2026 | marketbeat.com

Vaxcyte prices $1B in stock and note offerings

October 7, 2026 | streetinsider.com

Vaxcyte Prices $1 Bln In Concurrent Equity, Convertible Notes Offerings

October 7, 2026 | rttnews.com

Vaxcyte prices $500M equity offering and $500M convertible notes

October 7, 2026 | msn.com

BTIG Research Reaffirms Buy Rating for Vaxcyte (NASDAQ:PCVX)

October 7, 2026 | americanbankingnews.com

Vaxcyte Announces Pricing of Concurrent Public Offerings of Common Stock, Pre-Funded Warrants and Convertible Senior Notes

October 6, 2026 | globenewswire.com

Vaxcyte: 'Strong Buy' On VAX-31 Trial Win IPD VAX-31 And Additional Readouts 1st Half 2027

October 6, 2026 | seekingalpha.com

As Expected: Vaxcyte Announces $1 Billion Stock and Convertible Raise a Day After Its Phase 3 Win (and Sinks 10%)

October 6, 2026 | finance.yahoo.com

Stock Traders Buy High Volume of Put Options on Vaxcyte (NASDAQ:PCVX)

October 6, 2026 | marketbeat.com

Vaxcyte (NASDAQ:PCVX) Sees Large Volume Increase on Analyst Upgrade

October 6, 2026 | americanbankingnews.com

Vaxcyte (NASDAQ:PCVX) Sees Large Volume Increase Following Analyst Upgrade

October 6, 2026 | marketbeat.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

NAMS, IBRX, PCVX, and KRYS Company Descriptions

ImmunityBio NASDAQ:IBRX

$10.51 +0.60 (+6.05%)

Closing price 10/9/2026 04:00 PM Eastern

Extended Trading

$10.61 +0.10 (+0.95%)

As of 10/9/2026 07:59 PM Eastern

ImmunityBio, Inc., a clinical-stage biotechnology company, engages in developing therapies and vaccines that bolster the natural immune system to defeat cancers and infectious diseases. Its platforms for the development of biologic product candidates include antibody-cytokine fusion proteins; DNA, RNA, and recombinant protein vaccines; and cell therapies. The company's platforms have generated therapeutic agents that are currently being or planned to be studied in clinical trials across various indications in liquid and solid tumors, including bladder, lung and colorectal cancers, and glioblastoma multiforme. Its lead biologic product candidate is Anktiva, an FDA-approved immunotherapy in combination with bacillus calmette-guérin (BCG) for the treatment of adult patients with BCG unresponsive non-muscle invasive bladder cancer with carcinoma in situ, with or without papillary tumors. The company has collaboration agreements with National Cancer Institute. It also has license agreements with 3M Innovative Properties Company; Access to Advanced Health Institute; LadRx Corporation; Sanford Health; Shenzhen Beike Biotechnology Co. Ltd.; Viracta Therapeutics, Inc.; and GlobeImmune, Inc. The company is based in San Diego, California.

Krystal Biotech NASDAQ:KRYS

$331.61 +4.31 (+1.32%)

Closing price 10/9/2026 04:00 PM Eastern

Extended Trading

$327.07 -4.54 (-1.37%)

As of 10/9/2026 07:30 PM Eastern

Krystal Biotech, Inc., a commercial-stage biotechnology company, discovers, develops, and commercializes genetic medicines for patients with rare diseases in the United States. It commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB). The company also develops KB105, which is in Phase 1/2 clinical trials for treating patients with deficient autosomal recessive congenital ichthyosis; KB104 for treating netherton syndrome; KB407 that is in Phase 1 clinical trials for treating cystic fibrosis; KB707 that is in Phase 1 clinical trials for the treatment of anti-PD-1 relapsed/refractory; KB408, which is in Phase 1 clinical trials for treating Alpha-1 antitrypsin deficiency; and KB301 that is in Phase 2 clinical trials for treating aesthetic skin conditions, as well as in open label study with ophthalmic B-VEC for treating for ocular complications of deb. Krystal Biotech, Inc. was founded in 2016 and is headquartered in Pittsburgh, Pennsylvania.

NewAmsterdam Pharma NASDAQ:NAMS

$21.58 +0.32 (+1.51%)

Closing price 10/9/2026 04:00 PM Eastern

Extended Trading

$21.58 0.00 (0.00%)

As of 10/9/2026 07:57 PM Eastern

NewAmsterdam Pharma Company N.V., a late-stage biopharmaceutical company, develops therapies to enhance patient care in populations with metabolic disease. It is developing obicetrapib, an oral low-dose cholesteryl ester transfer protein (CETP) inhibitor, that is in various clinical trials as a monotherapy and a combination therapy with ezetimibe for lowering LDL-C for cardiovascular diseases. The company also develops Obicetrapib which is in Phase 2a clinical trial for Alzheimer's disease. NewAmsterdam Pharma Company N.V. is headquartered in Naarden, the Netherlands.

Vaxcyte NASDAQ:PCVX

$71.38 +6.37 (+9.80%)

Closing price 10/9/2026 04:00 PM Eastern

Extended Trading

$70.92 -0.46 (-0.64%)

As of 10/9/2026 07:54 PM Eastern

Vaxcyte, Inc., a clinical-stage biotechnology vaccine company, develops novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent investigational pneumococcal conjugate vaccine for the prevention of invasive pneumococcal disease. The company also develops VAX-31 to protect against emerging strains and to help address antibiotic resistance; VAX-A1, a novel conjugate vaccine candidate to prevent disease caused by Group A Streptococcus; VAX-PG, a novel protein vaccine candidate targeting keystone pathogen responsible for periodontitis; and VAX-GI to prevent Shigella, a bacterial illness. The company was formerly known as SutroVax, Inc. and changed its name to Vaxcyte, Inc. in May 2020. Vaxcyte, Inc. was incorporated in 2013 and is headquartered in San Carlos, California.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest NAMS, IBRX, PCVX, and KRYS Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest NAMS, IBRX, PCVX, and KRYS Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

NAMS, IBRX, PCVX, and KRYS Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

NAMS, IBRX, PCVX, and KRYS Company Descriptions

ImmunityBio NASDAQ:IBRX

Krystal Biotech NASDAQ:KRYS

NewAmsterdam Pharma NASDAQ:NAMS

Vaxcyte NASDAQ:PCVX

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest NAMS, IBRX, PCVX, and KRYS Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest NAMS, IBRX, PCVX, and KRYS Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

NAMS, IBRX, PCVX, and KRYS Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

NAMS, IBRX, PCVX, and KRYS Company Descriptions

ImmunityBio NASDAQ:IBRX

Krystal Biotech NASDAQ:KRYS

NewAmsterdam Pharma NASDAQ:NAMS

Vaxcyte NASDAQ:PCVX

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools